OpenAI board member Fidji Simo will transition from her Instacart role over the next few months to join OpenAI later this year, where Sam Altman says she will “focus on enabling our ‘traditional’ company functions to scale.”
The FDA met with OpenAI to discuss how the agency could use AI tools for a project called cderGPT, which may stand for the Center for Drug Evaluation, according to a report from Wired. This week, FDA Commissioner Marty Makary brought up goals to eventually shorten the drug approval process with AI.
Miles Klee at Rolling Stone reported out a widely circulated Reddit post on “ChatGPT-induced psychosis”:
Sycophancy itself has been a problem in AI for “a long time,” says Nate Sharadin, a fellow at the Center for AI Safety ... What’s likely happening with those experiencing ecstatic visions through ChatGPT and other models, he speculates, “is that people with existing tendencies toward experiencing various psychological issues,” including what might be recognized as grandiose delusions in clinical sense, “now have an always-on, human-level conversational partner with whom to co-experience their delusions.”
